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Dear Editor,
High hyperdiploidy with 51–67 chromosomes (HeH)
constitutes a large cytogenetic subset of B cell precursor
childhood acute lymphoblastic leukemia (ALL) [1]. It is
much less common in adult B cell precursor ALL where it
was reported in nearly 10% of patients for whom outcome
was improved compared to the other cytogenetic groups,
but not as favorable as in children [2, 3]. It is rarely found
in T cell or mature B cell ALL.
Automated four-color interphase fluorescence in situ
hybridization (I-FISH) previously revealed a high level of
clonal aneuploidy heterogeneity in HeH ALL at presentation
[4]. Numerical chromosome instability (CIN) was supposed
to be at the origin of this heterogeneity. To assess the
presence of clonal heterogeneity and numerical CIN in adult
HeH ALL at diagnosis and during disease course, we
focused on a series of ten ALL patients selected according
to the presence of HeH by conventional cytogenetics, age,
and availability of material for four-color I-FISH investiga-
tion using probes specific to chromosomes 4, 6, 10, and 17
(Supplement 1). Probes were chosen based on the frequent
gain of these chromosomes in HeH ALL and its prognostic
significance [5]. Patients were referred between 1995 and
2009 from the university hospitals of Basel, Zurich, Bern,
Lausanne and cantonal/regional hospitals of St-Gallen,
Aarau, Mendrisio, Bellinzona, and Genolier Clinic. Two
patients were enrolled in the SAKK ALL 33-86/90 [6] and
GRAALL 2005 clinical trials, respectively. Ethical approval
for this project was obtained in accordance with the
guidelines of the local Ethical Review Board.
Thirty-four samples were analyzed (presentation, 7;
hematologic remission, 19; relapse, 8); status of heterogeneity
and CIN level were determined (Table 1, Supplement 2).
Significant aneuploidies were identified based on cutoff
values defined according to the Poisson distribution, and
combinations of aneuploidies were considered relevant when
at least one aneuploidy was determined to be significant.
Average CIN was determined for all four chromosomes
together and then for each selected chromosome.
Approaches used and cutoff levels were reported in detail
previously [4, 7].
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High levels of clonal heterogeneity were observed at
diagnosis and during disease course, at relapse particularly.
Clones detected at presentation generally reappeared at
relapse, mostly accompanied by newly generated ones
(Supplement 3). Whereas the mean total number of
abnormal clones did not clearly differ between diagnostic
and relapse samples, the range of their variation did, being
much larger at relapse (Table 1). Despite the small number
of patients, a significant correlation was observed between
number of abnormal clones and CIN, suggesting that the
higher the instability, the larger the number of abnormal
clones (Fig. 1).
Data let surmise that the dynamic process at the origin
of HeH ALL is a complex one leading to coexistence of
sub-clones with different combinations of aneuploidy,
whose heterogeneity and variation result from a simultaneous
chromosome gain mechanism driven by underlying
chromosome instability and whose evolution will depend
on natural selection and acquisition of additional genetic
abnormalities [1, 8].
Given the poor outcome associated with CIN in solid
tumors and myelodysplastic syndromes [9, 10], the nature
and extent of clonal heterogeneity at diagnosis may be of
prognostic significance in HeH ALL. This question would
merit to be investigated in a large cohort of HeH ALL
patients.
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